IL272123A - Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions - Google Patents
Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventionsInfo
- Publication number
- IL272123A IL272123A IL272123A IL27212320A IL272123A IL 272123 A IL272123 A IL 272123A IL 272123 A IL272123 A IL 272123A IL 27212320 A IL27212320 A IL 27212320A IL 272123 A IL272123 A IL 272123A
- Authority
- IL
- Israel
- Prior art keywords
- tilmanocept
- 99mtc
- identifying
- malignant tumors
- therapeutic anti
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229950010544 tilmanocept Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535752P | 2017-07-21 | 2017-07-21 | |
| PCT/US2018/043176 WO2019018815A1 (en) | 2017-07-21 | 2018-07-20 | USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL272123A true IL272123A (en) | 2020-03-31 |
Family
ID=65014640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272123A IL272123A (en) | 2017-07-21 | 2020-01-19 | Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190022259A1 (https=) |
| EP (1) | EP3655107A4 (https=) |
| JP (1) | JP2020528059A (https=) |
| CN (1) | CN111447955A (https=) |
| CA (1) | CA3070494A1 (https=) |
| IL (1) | IL272123A (https=) |
| WO (1) | WO2019018815A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3127487A1 (en) * | 2019-01-25 | 2020-07-30 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for assessing macrophage mediated pathology |
| US20210052639A1 (en) * | 2019-08-19 | 2021-02-25 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells |
| US20210145989A1 (en) * | 2019-09-30 | 2021-05-20 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands |
| EP4076540A4 (en) * | 2020-07-08 | 2024-02-21 | Navidea Biopharmaceuticals, Inc. | Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof |
| CA3192041A1 (en) * | 2020-08-21 | 2022-02-24 | Resolute Science, Inc. | Compositions and methods for targeting tumor-associated macrophages |
| EP4472643A1 (en) | 2022-02-04 | 2024-12-11 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| US20230302041A1 (en) * | 2022-03-25 | 2023-09-28 | Navidea Biopharmaceuticals, Inc. | Competitive Self-Blocking with Unlabeled Manocept Imaging Agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671256A (en) * | 1984-05-25 | 1987-06-09 | Lemelson Jerome H | Medical scanning, monitoring and treatment system and method |
| US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| JP2005226021A (ja) * | 2004-02-16 | 2005-08-25 | Nihon Medi Physics Co Ltd | マンノース受容体親和性化合物 |
| CN114377143A (zh) * | 2013-07-22 | 2022-04-22 | 康德乐健康414有限责任公司 | 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| US20170202969A1 (en) * | 2014-07-17 | 2017-07-20 | Larry Schlesinger | Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same |
| CA2955438C (en) * | 2014-07-17 | 2024-07-02 | Ohio State Innovation Foundation | DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR |
| WO2016011419A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| US10806803B2 (en) * | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| WO2016118188A1 (en) * | 2015-01-21 | 2016-07-28 | Navidea Biopharmaceuticals, Inc. | Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells |
| WO2018067751A1 (en) * | 2016-10-04 | 2018-04-12 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier |
| MX2019004029A (es) * | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| EP3522899A4 (en) * | 2016-10-07 | 2020-05-06 | Navidea Biopharmaceuticals, Inc. | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same |
-
2018
- 2018-07-20 WO PCT/US2018/043176 patent/WO2019018815A1/en not_active Ceased
- 2018-07-20 JP JP2020502669A patent/JP2020528059A/ja active Pending
- 2018-07-20 US US16/041,673 patent/US20190022259A1/en not_active Abandoned
- 2018-07-20 CA CA3070494A patent/CA3070494A1/en active Pending
- 2018-07-20 CN CN201880061342.0A patent/CN111447955A/zh active Pending
- 2018-07-20 EP EP18834762.9A patent/EP3655107A4/en not_active Withdrawn
-
2020
- 2020-01-19 IL IL272123A patent/IL272123A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190022259A1 (en) | 2019-01-24 |
| CA3070494A1 (en) | 2019-01-24 |
| WO2019018815A1 (en) | 2019-01-24 |
| EP3655107A4 (en) | 2021-04-28 |
| JP2020528059A (ja) | 2020-09-17 |
| EP3655107A1 (en) | 2020-05-27 |
| CN111447955A (zh) | 2020-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272123A (en) | Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions | |
| IL274246A (en) | Methods for diagnosing and treating cancer | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL280707A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| IL273071A (en) | Treatment and diagnosis methods for cancer | |
| EP3806724A4 (en) | DETECTION AND CHARACTERIZATION OF CANCERUS TUMORS | |
| IL283625A (en) | Diagnostic methods and compositions for cancer immunotherapy | |
| CA185208S (en) | Medical probe | |
| EP3384269A4 (en) | METHOD FOR PREPARING AND ANALYZING TUMOR TISSUE SAMPLES FOR DETECTING AND MONITORING CANCER | |
| PH12015501744A1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
| ZA201801024B (en) | 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer | |
| AU201714303S (en) | Diagnostic instruments and apparatus | |
| EP3089660A4 (en) | Ultrasound-guided non-invasive blood pressure measurement apparatus and methods | |
| EP3270774A4 (en) | CONTINUOUS NON-INVASIVE MONITORING OF A PREGNANT PERSON | |
| IL276089A (en) | Methods for colon cancer detection and treatment monitoring | |
| IL253582B (en) | Detection and treatment of malignant tumours in the cns | |
| IL255104A0 (en) | MRI thermography for cardiac injury assessment | |
| IL284237A (en) | Imaging and treatment of tumors expressing somastatin receptor | |
| SG11202001796SA (en) | Bacteria for targeting tumors and treating cancer | |
| IL281556A (en) | Diagnostic methods for triple-negative breast cancer | |
| EP3698712A4 (en) | BRAIN WAVE ASSESSMENT SYSTEM, BRAIN WAVE ASSESSMENT PROCESS, NON-TRANSITIONAL RECORDING PROGRAM AND MEDIA | |
| IL271307A (en) | Methods of treating brain tumors using combination therapy | |
| EP3740755C0 (en) | USE OF THE TAS1R3 PROTEIN AS A MARKER FOR THERAPEUTIC, DIAGNOSTIC AND/OR PROGNOSTIC PURPOSES FOR TUMORS EXPRESSING THIS PROTEIN | |
| EP3639028A4 (en) | DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MALIGNE SOLID TUMORS | |
| PT3229830T (pt) | Métodos de tratamento e prognóstico de tumores malignantes não hematopoieticos |